Beam Therapeutics (BEAM) Stock Price, News & Analysis

Company Overview

Beam Therapeutics, Inc. (NASDAQ: BEAM) is a biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform. Headquartered in Cambridge, Massachusetts, with additional research facilities in Philadelphia, the company focuses on engineering molecular editors capable of making precise single-nucleotide changes in DNA. By harnessing its proprietary base editing technology, Beam aims to correct or disrupt disease-causing genetic variants at their source, offering the potential for novel therapies in areas with significant unmet medical need.

Founded in 2017 as a spin-out from Harvard University and the Broad and Whitehead Institutes, Beam was co-founded by leading academic researcher David R. Liu, Ph.D., and a team of genome-editing pioneers. Unlike traditional CRISPR/Cas9 approaches that create double-strand DNA breaks, Beam’s base editing platform converts one DNA letter into another through targeted enzymatic reactions, minimizing genomic disruption. The company’s pipeline includes ex vivo programs for monogenic blood disorders such as sickle cell disease and beta thalassemia, as well as in vivo candidates aimed at rare metabolic and genetic conditions. Strategic collaborations with major pharmaceutical partners support the translation of these programs into clinical development.

Since its initial public offering in early 2020, Beam Therapeutics has expanded its capabilities in research, development and manufacturing, forging partnerships to scale delivery and production of its novel editors. The company’s leadership team brings together seasoned executives and scientists with expertise in protein engineering, lipid nanoparticle delivery and regulatory strategy, all united by a commitment to advance next-generation precision therapies. As Beam progresses key programs toward clinical milestones, it remains focused on translating base editing innovations into safe and effective treatments for patients worldwide.

Key Stats

• Today's Range: $25.29 to $26.38
• 50-Day Range: $16.01 to $27.87
• 52-Week Range: $13.52 to $35.25
• Volume: 1.99 million shs
• Average Volume: 2.34 million shs
• Market Capitalization: $2.63 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $45.92
• Consensus Rating: Moderate Buy

Beam Therapeutics Stock Analysis - MarketRank™

Beam Therapeutics scored higher than 71% of companies evaluated by MarketBeat, and ranked 319th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Beam Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.94, and is based on 10 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Beam Therapeutics has a consensus price target of $45.92, representing about 76.7% upside from its current price of $25.98.

Amount of Analyst Coverage

Beam Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Beam Therapeutics are expected to grow in the coming year, from ($4.57) to ($4.27) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Beam Therapeutics is -5.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Beam Therapeutics is -5.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Beam Therapeutics has a P/B Ratio of 2.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

21.13% of the outstanding shares of Beam Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Beam Therapeutics has a short interest ratio ("days to cover") of 8.4.

Change versus previous month

Short interest in Beam Therapeutics has recently decreased by 16.16%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Beam Therapeutics does not currently pay a dividend.

Dividend Growth

Beam Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

21.13% of the outstanding shares of Beam Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Beam Therapeutics has a short interest ratio ("days to cover") of 8.4.

Change versus previous month

Short interest in Beam Therapeutics has recently decreased by 16.16%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.72

News Sentiment

Beam Therapeutics has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Beam Therapeutics this week, compared to 7 articles on an average week.

Search Interest

81 people have searched for BEAM on MarketBeat in the last 30 days. This is an increase of 65% compared to the previous 30 days.

MarketBeat Follows

23 people have added Beam Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 92% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Beam Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $991,667.00 in company stock.

Percentage Held by Insiders

Only 3.50% of the stock of Beam Therapeutics is held by insiders.

Percentage Held by Institutions

99.68% of the stock of Beam Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BEAM Stock Analysis - Frequently Asked Questions

How have BEAM shares performed this year?

Beam Therapeutics' stock was trading at $24.80 at the beginning of the year. Since then, BEAM shares have increased by 4.8% and is now trading at $25.98.

How were Beam Therapeutics' earnings last quarter?

Beam Therapeutics Inc. (NASDAQ:BEAM) released its earnings results on Tuesday, August, 5th. The company reported ($1.00) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.04) by $0.04. The firm's revenue was down 28.0% on a year-over-year basis.

Does Beam Therapeutics have any subsidiaries?

Beam Therapeutics subsidiaries include Blink Therapeutics Inc..

When did Beam Therapeutics IPO?

Beam Therapeutics (BEAM) raised $101 million in an initial public offering (IPO) on Thursday, February 6th 2020. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and Barclays acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Beam Therapeutics' major shareholders?

Top institutional shareholders of Beam Therapeutics include Voya Investment Management LLC (0.02%) and World Investment Advisors (0.01%). Insiders that own company stock include Fmr Llc, John M Evans, Giuseppe Ciaramella, Christine Bellon, Terry-Ann Burrell, Amy Simon and Bethany J Cavanagh.
View institutional ownership trends.

How do I buy shares of Beam Therapeutics?

Shares of BEAM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Beam Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Beam Therapeutics investors own include Chevron (CVX), Bristol Myers Squibb (BMY), Comcast (CMCSA), Charles Schwab (SCHW), Edwards Lifesciences (EW), McKesson (MCK) and Yum! Brands (YUM).

Company Calendar

• Last Earnings: 8/05/2025
• Today: 10/18/2025
• Next Earnings (Estimated): 11/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BEAM
• CIK: 1745999
• Web: www.beamtx.com
• Phone: 857-327-8775
• Fax: N/A
• Employees: 510
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Beam Therapeutics: $45.92
• High Price Target: $80.00
• Low Price Target: $21.00
• Potential Upside/Downside: +76.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.94
• Research Coverage: 16 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$376.74 million
• Net Margins: -661.31%
• Pretax Margin: -661.31%
• Return on Equity: -43.15%
• Return on Assets: -31.06%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.75
• Quick Ratio: 6.75

Sales & Book Value

• Annual Sales: $63.52 million
• Price / Sales: 41.37
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.86 per share
• Price / Book: 2.93

Miscellaneous

• Outstanding Shares: 101,160,000
• Free Float: 97,621,000
• Market Cap: $2.63 billion
• Optionable: Optionable
• Beta: 2.25